FLOW trial: difference between revisions
Diff·revision 2 → 3·21:12, 9 Oct 2024
Difference between revision 2 and revision 3 of FLOW trial. 6 lines changed; the page grew by 752 bytes.
| Revision 2 — 03:33, 30 Sep 2024 LeanMassLars (talk) expand §Results 1,198 bytes ±0 | Revision 3 — 21:12, 9 Oct 2024 LotTraceLuka (talk) correct the endpoint hierarchy — that was a secondary endpoint 1,950 bytes +752 | ||
|---|---|---|---|
| 11 | The primary composite comprised onset of kidney failure, a sustained fall of at least 50% in estimated glomerular filtration rate, or death from kidney or cardiovascular causes. It occurred less often on semaglutide, hazard ratio 0.76 (95% CI 0.66–0.88).{{r|perkovic2024}} | 11 | The primary composite comprised onset of kidney failure, a sustained fall of at least 50% in estimated glomerular filtration rate, or death from kidney or cardiovascular causes. It occurred less often on semaglutide, hazard ratio 0.76 (95% CI 0.66–0.88).{{r|perkovic2024}} |
| 12 | 12 | ||
| + | 13 | == Design == | |
| + | 14 | Participants had type 2 diabetes with an estimated glomerular filtration rate and albumin-to-creatinine ratio within defined ranges, and were on maximum tolerated renin–angiotensin system blockade. The trial therefore tested semaglutide added to established renal protection rather than in its place.{{r|perkovic2024}} | |
| + | 15 | ||
| + | 16 | The dose studied was 1.0 mg weekly — the type 2 diabetes dose, not the 2.4 mg obesity dose. As elsewhere in this field, results at one dose do not transfer to another.{{r|lincoff2023}} | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |
| 15 | <ref name="perkovic2024">Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." ''New England Journal of Medicine'' 391(2):109–121 (2024). DOI:10.1056/NEJMoa2403347. PMID 38785209.</ref> | 20 | <ref name="perkovic2024">Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." ''New England Journal of Medicine'' 391(2):109–121 (2024). DOI:10.1056/NEJMoa2403347. PMID 38785209.</ref> |
| + | 21 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | |
| 16 | 22 | ||
| 17 | {{DEFAULTSORT:FLOW trial}} | 23 | {{DEFAULTSORT:FLOW trial}} |